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                     Dynamic Contrast-EnhancedMagnetic Resonance Imaging of
Ocular Melanoma as a Tool to Predict Metastatic PotentialWenbo Wei, PhD,* Guang Jia, PhD,*† Hendrik von Tengg-Kobligk, MD,*‡
Johannes T. Heverhagen, MD, PhD,*‡ Mohamed Abdel-Rahman, MD, PhD,§ Lai Wei, PhD,||
John B. Christoforidis, MD,§¶ Frederick Davidorf, MD,§ and Michael V. Knopp, MD, PhD*Purpose: This study explores the capability of dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) to differentiate tumor character-
istics of metastatic and nonmetastatic choroidal melanoma as a potential
tool for patient management.
Materials and Methods: A total of 13 patients (69 ± 9 years) with
choroidal melanoma were imaged using DCE-MRI on a 3-T MRI system
with a 16-channel head coil. The Tofts 2-compartment model was chosen
for quantification, and parameters Ktrans (the transfer constant from the
blood plasma to the extracellular space) andKep (the transfer constant from
the extracellular space to the blood plasma) were calculated and compared.
Metastasis was excluded by subsequent clinical work-up or confirmed by
histology after targeted biopsy.
Results: Six patients were diagnosed with metastatic melanoma and
7 without. All orbital tumors were at least larger than 2 mm. A significant
difference was identified in Ktrans between patients with (0.73 ± 0.18/min)
and without (1.00 ± 0.21/min) metastatic melanoma (P = 0.03), whereas
the difference was not significantly shown in Kep (2.58 ± 1.54/min of
metastatic patients vs 2.98 ± 1.83/min of nonmetastatic patients, P = 0.67).
Conclusions: Dynamic contrast-enhanced magnetic resonance imaging
has the potential to differentiate orbital melanomas with metastatic and
nonmetastatic spread. Thus, DCE-MRI has the potential to be an in vivo
imaging technique to predict earlywhich patients are prone tometastatic disease.
KeyWords: choroidal melanoma, metastasis, dynamic contrast-enhanced
magnetic resonance imaging, Ktrans
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M alignant melanoma of the choroid is the most common typeof primary intraocular malignancy in adults. It is caused by
the uncontrolled pigmented cells growing in the eye. In the United
States, the yearly mean incidence of choroidal melanoma is re-
ported to be 6 to 7 cases per million people. Choroidal melanoma
is more commonly seen in an older age group, with a progressively
rising age-specific incidence rate that peaks at the age of 70 years.
At the time of diagnosis, 99.5% of the patients have “no evidence
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frommetastatic melanoma.2,3More than 90% of patients with me-
tastasis show liver involvement.4,5 Therefore, early detection of
metastasis may reduce its spread rate and help in clinical treatment
planning and therapy assessment.6
It is assumed that metastasis is via hematogenous spread.
Rapid progress has been made in the development of dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI) in
oncology by providing, in addition to detailed morphology,7 at
the same time, spatially resolved functional information.8–10 Over
the past decades, it has been established that changes in angiogen-
esis are a key factor in tumor growth and development.11 Folberg
et al12 and Mehaffey et al13 have found direct correlation between
the microvasculature of malignant melanoma and survival rates. It
has been shown that time-resolved MRI is able to noninvasively
visualize characteristic pharmacokinetic patterns of a contrast agent
passing through the microvasculature of tumors, which can provide
useful prognostic information for cancer patients.14–16 Based on a
mathematical model, pharmacokinetic parameters can be calculated
using a dedicated postprocessing environment, which can be used
to improve noninvasive tumor characterization.17 Thus, DCE-MRI
could provide a more specific in vivo analysis of the microcirculation
of choroidal tumors than previous methods.18 This has been demon-
strated successfully in different kinds of tumors (eg, breast cancer)
with MRI and other imaging modalities.19–22
The potential of DCE-MRI–derived parameters has been
reported to be able to assess the metastatic potential of mela-
noma.23 The studies on human melanoma xenografts revealed
the correlation between the tumor tissue blood transfer rate
(Ktrans) and the tumor aggressiveness and the extent of hypoxia
in animal models. Although the tumors in general have increased
angiogenesis, the more aggressive metastatic tumors are likely to
produce more blood vasculature.24 However, the high cell density
with lack of oxygen and nutrition supply leads to less functional
blood vessels. The potential that DCE-MRI may provide addi-
tional information at the molecular level was investigated in the
study. In this retrospective study, patients with metastatic and
nonmetastatic melanoma have been imaged to determine the
quantitative assessment of dynamic contrast enhancement and
examine its potential correlation to metastasis of the choroidal
melanoma. The parameters Ktrans (the transfer constant from the
blood plasma to the extracellular space) and Kep (the transfer con-
stant from the extracellular space to the blood plasma) from the Tofts
2-compartment model were compared between the 2 groups.22,25
MATERIALS AND METHODS
Patients
More than 50 patients were referred by ophthalmologists for
3-T MRI from May 2006 to March 2012 in patients with intraoc-
ular space occupying lesions, and imaging included DCE-MRI.
Thirteen patients (7 men and 6 women; age, 69 ± 9 years) withwww.jcat.org 1
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TABLE 1. Patient Demographic Information
Patient
No. Sex
Age at
Examination
Ocular Tumor
Volume, mm3
Metastasis
Information
P01 Female 48 146 No
P02 Male 78 813 No
P03 Male 56 505 No
P04 Female 75 572 No
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                      no renal dysfunction and those with a tumor diameter greater than
2mmwere included in this evaluation. The tumor volumewas cal-
culated by measuring the tumor volume in each consecutive slice
and adding them together. A total of 14 ocular lesions were diag-
nosed. All patients previously agreed to participate in the research
evaluation. All examinations were performed in accordance with
the approval of the institutional review board. Subsequent to the
eye MRI, the patients received clinical staging that included oph-
thalmologic examinations and other imaging studies. When a me-
tastasiswas noted, it was histologically verified after targeted biopsy.P05 Female 75 193 No
P06 Female 69 1453 Metastatic lesion
within the spine
and the liver
2476*
P07 Male 69 2116 Metastatic liver
lesion
P08 Male 66 1462 Metastatic liver
lesion
P09 Male 72 861 No
P10 Female 78 1624 No
P11 Male 70 4677 Metastatic liver
lesion
P12 Male 59 274 Metastatic liver
lesion
P13 Female 78 7763 Metastatic liver
lesion
The ocular tumor volume and the sites of metastasis are listed.
*Patient has a second ocular tumor.Dynamic Contrast-Enhanced MRI
Magnetic resonance imaging was performed using a 3-T
whole-body MRI system (Achieva; Philips, Cleveland, Ohio)
using a 32-channel phased-array head coil. Before performing
DCE-MRI, T1-weighted images at coronal, sagittal, and axial
planes, axial T2-weighted images, 3D T1-weighted high resolution
images, and axial diffusion-weighted images were acquired for
reference. For the dynamic imaging, a coronal 3D T1-weighted
fast field echo sequence (also known as T1-weighted spoiled
gradient echo) was acquired with fat suppression. Other param-
eters were TR/TE = 4.2/2.2 milliseconds, flip angle = 15 degrees,
fieldofview=18018032mm3,voxel size=0.90.92mm3,
temporal resolution = 9 seconds, oversampling factor = 1.28, turbo
factor = 50, number of slices = 16, number of signal average = 1,
and no parallel imaging. After the start of the dynamic MR acqui-
sition, 5 to 8 scans were made to serve as baseline before contrast
injection. A total of 50 dynamic temporal points were acquired.
The contrast agent Magnevist (Gd-DTPA2−; Bayer, Germany)
was administered intravenously at a standard bolus dose of
0.1 mmol/kg body weight at a rate of 0.6 mL/s immediately
followed by a 15-mL saline flush.9 The total of DCE-MRI acqui-
sition was made within 6 to 8 minutes, depending on the slice
number. The patients were instructed to keep their eyes closed
and limit eyeball movement during the scan.FIGURE 1. The AIF of ophthalmic artery at the same side of the
choroidal lesion. Patient P07 was chosen, and the image at the
21st temporal point was shown.
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The dynamic MR image data sets were postprocessed using
in-house–developed software based on the Interactive Data
Language (Exelis Visual Information Solutions, Boulder, Colo)
environment. The pharmacokinetic analysis was applied to the
contrast-enhanced signal based on the Tofts 2-compartment
model.22 The region of interest (ROI) of the ophthalmic artery
at the same side of the choroidal lesion was used to calculate the
arterial input function (AIF) (Fig. 1). The subsequent output color
map was calculated automatically. The DCE-MRI parameters
Ktrans (the transfer constant from the blood plasma to the extracel-
lular space) and Kep (the transfer constant from the extracellular
space to the blood plasma) were obtained. The contours of
the primary site of the choroidal melanoma in the central slice
were manually drawn for the ROI analysis. The ROIs were
drawn by a clinical scientist with more than 5 years of experience
in musculoskeletal research. The necrotic areas were excluded
from the ROIs based on the axial T2-weighted images.
Statistical Analysis
The MRI quantitative parameters Ktrans and Kep of the
primary sites were tested for normality using Kolmogorov-
Smirnov test. Because Ktrans and Kep were normally distributed
(P > 0.15), they were compared between the metastatic and
nonmetastatic patients using 2 sample t tests. A P value of less
than 0.05 was considered to represent a significant difference.
Statistical analysis was performed using Statistical Analysis Sys-
tem v. 9.4 (SAS Institute, Cary, NC).RESULTS
Of the total 13 patients with eye melanoma, 6 patients were
diagnosed with metastatic lesions at various locations confirmed© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 2. The distribution of Ktrans (A) and Kep (B) according to the biopsy diagnosis on metastatic and nonmetastatic patients.
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                     with histologic diagnosis. It revealed that 5 patients had metastatic
liver lesions and 1 patient had metastatic lesions in both the spine
and the liver, whereas the remaining 7 cases did not show any me-
tastasis. The patients with and without metastasis were divided
into 2 groups, and the DCE-MRI parameters were compared.
Table 1 lists the patient demographic information. The ocular
tumor volume sizes were compared between the nonmetastatic
and metastatic patients. Although no significant difference could
be confirmed, the metastatic tumors trended to have a greater
volume on average than nonmetastatic tumors (2889 ± 2538 vs
674 ± 501 mm3, P = 0.06). The location of metastasis is listed
for each patient.
The results of Ktrans and Kep comparison between the meta-
static and nonmetastatic patients are plotted in Figure 2. The mean
and SD values of Ktrans and Kep are presented using solid and
dashed lines. The Ktrans of metastatic patients (0.73 ± 0.18/min,
n = 6) are statistically lower than the nonmetastatic ones
(1.00 ± 0.21/min, n = 7) (P = 0.03), whichmeans that the metastatic
patient's eye lesion has a higher contrast agent transfer from blood
plasma to extracellular space. No significant difference was found
in Kep (2.58 ± 1.54/min of metastatic patients vs 2.98 ± 1.83/min
of nonmetastatic patients) (P = 0.67).FIGURE 3. The time-intensity curves for metastatic (A, patient P06, 10th
point) patients. Region of interests were manually drawn on the DCE-M
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metastatic and nonmetastatic lesions in the DCE-MRI series are
shown in Figure 3 upper row, the associated time-intensity curves
in the bottom row. On the longitudinal axis, the signal intensity at
each time point was normalized to the average signal intensity
before the contrast agent wash in. For the postcontrast T1 images,
the time point was chosen when the contrast agent washed in and
reached the peak value. The eye tumor without metastasis shows a
much higher contrast agent uptake value that makes it brighter on
the T1 image. The ophthalmic arteries presented with intense en-
hancement and were used for the calculation of the AIF. In the
time-intensity curves, the nonmetastatic tumor has a rapidly
increasing slope that corresponds to the higher Ktrans values
than found in nonmetastatic patients. The peak value was found
to be approximately 2.11 for the nonmetastatic and 1.32 for the
metastatic tumor.
The Ktrans-coded color maps of 1 patient with metastasis and
1 patient without metastasis are presented in Figure 4. In the
metastatic patient, a large spinal metastasis was found within
the L4 vertebral body, and an intermediate subcentimeter lesion
was found within the L3 vertebral body. The ocular lesion with
metastasis presents heterogeneous Ktrans distribution with antemporal point) and nonmetastatic (B, patient P09, 12th temporal
RI images.
www.jcat.org 3
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FIGURE 4. The Ktrans-coded color maps of metastatic (A, patient P06) and nonmetastatic (B, patient P05) patients were shown.
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                      average value of approximately 0.61/min. The lesion with no me-
tastasis shows higher Ktrans values with an average of 1.17/min.
High Ktrans values are also seen in the blood vessels.DISCUSSION
Current cross-sectional imaging techniques have evolved
with improved spatial resolution to enable noninvasive morpho-
logic imaging of ocular and orbital structures. Nevertheless, the
ability to distinguish between tumors with metastasis and without
metastasis remains a challenge. To overcome this, additional in-
depth tumor microcirculatory information needs to be obtained.
Malignant melanoma is the tumor entity with the fastest rise
in incidence, and also, noninvasive imaging approaches as needed
because of the inability to readily biopsy the eye. Malignant
melanoma is known to have a high expression of vascular en-
dothelial growth factor. Dynamic contrast-enhanced magnetic
resonance imaging is known to reveal different contrast en-
hancement patterns in relation to microvasculature and expres-
sion of angiogenetic factor such as vascular endothelial growth
factor.23,26,27 The study is innovative because so far, very few
studies have applied pharmacokinetic modeling such as DCE-
MRI to the ocular and orbital region in vivo.
This study shows that Ktrans is significantly lower in the
metastatic than the nonmetastatic melanoma. When the contrast
agent is injected into the blood vessels, it is more difficult for
the contrast agent to diffuse into the extracellular space in the
ocular melanoma that leads to metastatic spread. It may indicate
that the blood vessels in the metastatic melanoma are less func-
tional than the nonmetastatic melanoma. Although more blood
vessels are needed for cancer cells to spread to other areas of the
body and form new tumors at metastatic sites, they seem to have
less patency and limited blood perfusion for oxygen and substrates.
It has been reported by Chikui et al28 that the Ktrans decrease
significantly correlated with the progression of the N stage in clin-
ical patients with oral squamous cell carcinoma. They speculated
that the reduced Ktrans and blood flow may lead to the hypoxic
state and higher likelihood of metastasis. Li et al29 conducted
DCE-MRI studies on 2 types of melanoma xenografts, including
the most metastatic, C8161, and the least metastatic, A375P. Sta-
tistically significant higher Ktrans was observed in A375P com-
pared with C8161, which showed that Ktrans in the tumor could
help distinguish between highly metastatic and least metastatic
melanomas. Similar results were found in the research by an inde-
pendent group.30 CK-160 cervical carcinoma and V-27melanoma4 www.jcat.org
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Ktrans and νe were produced. It showed that highly metastatic
tumors presented lower Ktrans values (P = 0.00033), whereas νe
showed lower values, but not significant, between metastatic and
nonmetastatic tumors (P > 0.05). Those observations are consis-
tent with our results obtained in ocular melanoma patients.
One limitation of this study is the relatively small number of
subjects. One of the reasons is because the patients with lesion di-
ameter less than 2 mm were excluded to avoid significant partial
volume effect in the analysis. It limited the statistical power of
the results and made the SD of data analysis large. The second
limitation is that only the central slice through the tumor was
chosen for analysis. Although the tumor center was expected
to be included, the ROIwas not able to display theKtrans distribution
throughout the whole tumor. An ROI covering the entire tumor
except the necrotic area may be used to generate Ktrans. Because
only a single observer defined the ROI contours, the interobserver
reliability was not tested. Another limitation is tumor-related other
factors were not considered, such as the degree of primary tumor.
Those characteristics may contribute to the Ktrans findings. Recent
publications have shown that variations were found in Ktrans and
νe calculations using different analysis software packages
31; we
used our well-established and validated in-house–developed Inter-
active Data Language environment.9 More analysis needs to be done
using different software to explore the intersoftware consistency.CONCLUSIONS
It was shown that DCE-MRI can differentiate the tumor
characterization between metastatic and nonmetastatic melanoma
by the Ktrans value. Thus, DCE-MRI has the potential to be an in
vivo imaging technique to indicate which patients are prone to
metastatic disease and may be an appropriate tool to stratify
therapeutic approaches.REFERENCES
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